FMP
Xenon Pharmaceuticals Inc.
XENE
NASDAQ
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
35.32 USD
0.14 (0.396%)
XENE Financial Statements
Year
2024
2023
2022
2021
Current Assets
635.26M
644.96M
600.3M
559.02M
Cash & Short Term Investments
626.9M
638.08M
592.09M
551.77M
Cash And Cash Equivalents
142.71M
148.64M
57.24M
175.69M
Short Term Investments
484.19M
489.44M
534.85M
376.09M
Net Receivables
1.47M
874k
986k
2.77M
Inventory
0
0
-986k
-2.77M
Other Current Assets
6.89M
6.01M
7.22M
0
Non-Current Assets
27.88M
319.84M
153.85M
12.99M
Property, Plant & Equipment
18.22M
18.85M
16.91M
12.52M
Goodwill And Intangible Assets
0
0
0
0
Goodwill
0
0
0
0
Intangible Assets
0
0
0
0
Long Term Investments
0
292.79M
128.68M
0
Tax Assets
9.67M
802k
509k
465k
Other Non-Current Assets
0
7.4M
7.75M
0
Other Assets
134.99M
0
0
0
Total Assets
798.14M
964.8M
754.15M
572.01M
-
-
-
-
Current Liabilities
35.59M
27.27M
22.7M
14.32M
Accounts Payable
5.07M
8.6M
8.49M
3.82M
Short Term Debt
0
0
0
0
Tax Payables
5.69M
0
0
0
Deferred Revenue
0
0
0
9.29M
Other Current Liabilities
9.93M
347k
7.9M
3.95M
Total Current Liabilities
35.59M
27.27M
22.7M
14.32M
Total Non-Current Liabilities
34.22M
9.6M
9.95M
7.65M
Long-Term Debt
0
0
0
0
Deferred Revenue
0
0
0
0
Deferred Taxes Liabilities
0
0
509k
0
Other Non Current liabilities
26.57M
0
0
0
Total Liabilities
43.24M
36.88M
32.65M
21.97M
Other Liabilities
-26.57M
0
0
0
Stockholders Equity
754.9M
927.92M
721.5M
550.03M
Common Stock
1.46B
1.44B
1.07B
783.17M
Retained Earnings
-899.47M
-665.14M
-482.75M
-357.37M
Accumulated Other Comprehensive Income/Loss
-1.61M
-77k
-3M
-990k
Other Shareholders Equity
199.15M
0
0
0
Total Liabilities and Stockholders Equity
798.14M
964.8M
754.15M
572.01M
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-665.14M
-482.75M
-357.37M
-278.49M
Net Income
-234.33M
-182.39M
-125.37M
-78.88M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-899.47M
-665.14M
-482.75M
-357.37M
Other Distributions
-234.33M
-182.39M
-125.37M
-78.88M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
18.22M
18.85M
16.91M
12.52M
Annual Depreciation
0
3.54M
1.62M
906k
Capital Expenditure
0
-5.62M
-2.89M
-2.05M
Net PPE
18.22M
20.92M
18.18M
13.67M
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
